Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. / (Record no. 1182)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03620naa a22004697i 4500 |
| 001 - CONTROL NUMBER | |
| control field | UMUN-OA-20261005-MLS-040 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | local |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20261005174904.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 261005s2023 xx o u000 0 eng d |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1038/s41392-023-01521-5 |
| Source of number or code | doi |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (local)EuropePMC:PMC10435569 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | local |
| Language of cataloging | eng |
| Transcribing agency | local |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lu Tang |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. / |
| Statement of responsibility, etc. | Lu Tang; Zhongpei Huang; Heng Mei [and others]. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | [Place of publication not identified] : |
| Name of producer, publisher, distributor, manufacturer | Nature Publishing Group, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 article). |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Publication type: Review article. |
| 500 ## - GENERAL NOTE | |
| General note | Linked open-access copy: published version. |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open access; no subscription required for the linked open-access version. |
| Standardized terminology for access restriction | Unrestricted online access |
| Source of term | star |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc. | The immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons Attribution. See the linked licence for the applicable terms. |
| Uniform Resource Identifier | <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a> |
| 546 ## - LANGUAGE NOTE | |
| Language note | In English. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Course allocation: B. Sc. Medical Laboratory Science. |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | B. Sc. Medical Laboratory Science |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | UMUN open access collection |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | hematology |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Review articles. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zhongpei Huang |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Heng Mei |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yu Hu |
| Relator term | author. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Signal transduction and targeted therapy |
| Related parts | Vol. 8, no. 1, (2023), pages/article 306 |
| International Standard Serial Number | 2095-9907 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://europepmc.org/articles/PMC10435569">https://europepmc.org/articles/PMC10435569</a> |
| Link text | Read open-access publication |
| Public note | Open access. |
| Access status | 0 |
| 884 ## - DESCRIPTION CONVERSION INFORMATION | |
| Conversion process | Course selection and automated MARC21 enrichment from Europe PMC metadata. |
| Conversion date | 20261005 |
| Identifier of source metadata | https://europepmc.org/articles/PMC10435569 |
| Conversion agency | local |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
No items available.